Nuvation Bio NUVB
NYSE NUVB
$5.34 -0.22 (-3.87%)
As of: Oct 2, 2026 · 10:30 AM EDT

Nuvation Bio (NUVB) Non-Current Deffered Revenue (2024 - 2026)

Updated

Nuvation Bio's Non-Current Deffered Revenue was $151.12 million in Q2 2026, up 5.8% from $142.78 million a year earlier but down 0.5% from the prior quarter.

Analysis

Nuvation Bio (NUVB) Non-Current Deffered Revenue (2024 - 2026) Analysis & Trends

At the end of FY2025, Non-Current Deffered Revenue at Nuvation Bio came in at $145.82 million.

  • Quarterly Non-Current Deffered Revenue has moved between $7.94 million (Q3 2024) and $151.89 million (Q1 2026) over five years.
  • Per Business Quant data, NUVB's Non-Current Deffered Revenue in the three quarters before Q2 2026 was $151.89 million (Q1 2026), $145.82 million (Q4 2025) and $144.62 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Nuvation Bio 1.94 Bn 1.94 Bn - 151.12 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 151.12 Mn
Mar 31, 2026 151.89 Mn
Dec 31, 2025 145.82 Mn
Sep 30, 2025 144.62 Mn
Jun 30, 2025 142.78 Mn
Mar 31, 2025 13.61 Mn
Sep 30, 2024 7.94 Mn
Jun 30, 2024 9.16 Mn
API Access

Nuvation Bio Non-Current Deffered Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=NUVB&period=max&api_key=YOUR_API_KEY